Covaxin: Already meets the continuous listing standards of the Nasdaq Global Market.

date
16/06/2026
Kexing Biotech Co., Ltd. announced on June 15th that the company has received a notification from NASDAQ Listing Qualifications on June 10th, confirming that it is now in compliance with Rule 5250 and has met the continued listing standards of NASDAQ Global Market.
Latest
See all latestmore